Comparative Pharmacology
Head-to-head clinical analysis: REXULTI versus SEZABY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REXULTI versus SEZABY.
REXULTI vs SEZABY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial agonist at D2 and 5-HT1A receptors; antagonist at 5-HT2A and α1B/α2C adrenergic receptors.
Positive allosteric modulator of GABA-A receptors, enhancing inhibitory neurotransmission.
2 mg orally once daily initially; increase to 4 mg once daily no sooner than week 2; target dose 4 mg once daily; range 2-4 mg once daily.
58 mg subcutaneously once monthly (every 30 days).
None Documented
None Documented
Terminal elimination half-life is approximately 19–23 days for brexpiprazole and its major metabolite DM-3411, requiring up to 2–3 months to reach steady state.
The terminal elimination half-life of Sezaby is approximately 24 hours in healthy adults. This supports once-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Approximately 25% of the dose is excreted in urine as unchanged drug and metabolites; about 54% is excreted in feces. Renal excretion of unchanged drug is minor (<1%).
Sezaby undergoes extensive hepatic metabolism, with approximately 75% of the dose excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites. Renal clearance accounts for less than 5% of total clearance.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic